PACIFIC NORTHWEST PROSTATE CANCER SPORE

西北太平洋前列腺癌孢子

• 批准号: 7096579
• 负责人: PAUL H. LANGE
• 金额: $ 252.39万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-19 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7096579
• 关键词: clinical research; human subject; neoplasm /cancer genetics; prostate neoplasms

DESCRIPTION (provided by applicant): The Pacific Northwest Prostate Cancer SPORE is a coordinated effort of four institutions with strong programs in prostate cancer research and career development: 1) the Fred Hutchinson Cancer Research Center (FHCRC); 2) the University of Washington (UW) and its affiliated institutions; 3) the Institute for Systems Biology (ISB); and 4) the University of British Columbia and the Prostate Center & Institute of Vancouver General Hospital. These three Seattle-based and the British Columbia (BC)-based institutions have a large number of investigators and laboratories dedicated to prostate cancer (CAP) research. Within this milieu, there already exists substantial technical infrastructure (e.g., genomics), strong multidisciplinary expertise (e.g., molecular biology, biochemistry, epidemiology, genetics, medical & radiation oncology, urology), and extensive resources (e.g., serum, DNA & tissue banks, CaP animal model facilities, CaP genomic arrays, and a CaP clinical trials organization). All four institutions have, and are in the process of generating, increasing resources for programs in translational CaP research and are committed to contributing significant resources toward the goals of this SPORE. The purpose of the SPORE is not only to perform the research projects proposed, but in a larger sense to form the "central supporting piece" to a large developing "mosaic" of coordinated translational CaP research in the Pacific Northwest. We believe the projects to be innovative and translational. Project 1 is a population-based study evaluating specific genetic polymorphisms in relation to CaP progression/mortality. Project 2 aims to characterize molecular alterations (karyotype, transcript) of disseminated CaP cells in the context of influencing the clinical management of patients as diagnostic and prognostic indicators. Project 3 will identify critical determinants of the transition from androgen-dependent to androgen-independent CaP, and will validate these findings in well-characterized pre-clinical models and clinical trials. Project 4 seeks to expand our already extensive work on the genomics of CaP and will determine if tumor gene expression profiles can predict the course of disease and response to cytotoxic chemotherapy. We have proposed five Cores in support of these projects (Administration, Specimen/Tissue, Biostatistics, Informatics & Gene Expression, and Clinical Research). The Career Development and Pilot Project Programs we propose will significantly embellish and strengthen the translational orientation of our prostate cancer research and expand opportunities for new investigators.

描述（由申请人提供）： 太平洋西北前列腺癌 SPORE 是四个机构的协调努力，在前列腺癌研究和职业发展方面拥有强大的项目：1) Fred Hutchinson 癌症研究中心 (FHCRC)； 2）华盛顿大学（UW）及其附属机构； 3）系统生物学研究所（ISB）； 4) 不列颠哥伦比亚大学和温哥华总医院前列腺中心和研究所。这三个位于西雅图和不列颠哥伦比亚省 (BC) 的机构拥有大量致力于前列腺癌 (CAP) 研究的研究人员和实验室。在这个环境中，已经存在大量的技术基础设施（例如基因组学）、强大的多学科专业知识（例如分子生物学、生物化学、流行病学、遗传学、医学和放射肿瘤学、泌尿学）以及广泛的资源（例如血清、DNA 和组织）银行、Cap 动物模型设施、Cap 基因组阵列和 Cap 临床试验组织）。所有四个机构都已经并且正在为转化性 CaP 研究项目增加资源，并致力于为实现该 SPORE 的目标贡献大量资源。 SPORE 的目的不仅是执行所提出的研究项目，而且从更大的意义上说，是为西北太平洋地区协调转化 CaP 研究的大型发展“马赛克”形成“核心支撑部分”。 我们相信这些项目具有创新性和转化性。项目 1 是一项基于人群的研究，评估与 CaP 进展/死亡率相关的特定遗传多态性。项目 2 旨在描述播散性 CaP 细胞的分子改变（核型、转录本），作为诊断和预后指标，影响患者的临床管理。项目 3 将确定从雄激素依赖型到雄激素非依赖型 CaP 转变的关键决定因素，并将在充分表征的临床前模型和临床试验中验证这些发现。项目 4 旨在扩展我们在 CaP 基因组学方面已经广泛的工作，并将确定肿瘤基因表达谱是否可以预测病程和对细胞毒性化疗的反应。 我们提出了五个核心来支持这些项目（管理、样本/组织、生物统计学、信息学和基因表达以及临床研究）。我们提出的职业发展和试点项目计划将显着完善和加强我们前列腺癌研究的转化方向，并为新研究人员提供更多机会。